<DOC>
	<DOCNO>NCT00964028</DOCNO>
	<brief_summary>This study evaluate safety reactogenicity Infanrix-IPV/Hib give three-dose primary vaccination course healthy infant 2-3-4 3-4-5 month age .</brief_summary>
	<brief_title>Safety Study GSK Biologicals ' DTPa-IPV/Hib ( Infanrix™-IPV/Hib )</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female infant , include , 60 90 day age time first study visit . Born gestation period 36 42 week inclusive . Subjects investigator believe parents/guardians comply requirement protocol enrol study . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period , exception hepatitis B vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous intercurrent diphtheria , tetanus , pertussis , poliomyelitis and/or Hib disease . Previous vaccination diphtheria , tetanus , pertussis , poliovirus and/or Haemophilus influenzae type b disease . History seizure progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . The following condition temporary selflimiting subject may vaccinate condition resolve exclusion criterion meet : • Current febrile illness axillary temperature &gt; 37.0 ºC moderate severe illness within 24 hour study vaccine administration .</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Combined vaccine</keyword>
</DOC>